This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Newron Pharmaceuticals SpA
Drug Names(s): NW-1015, ME2125, ME 2125
Description: Safinamide has multiple mechanisms of action:
- Inhibition of dopamine uptake.
- Selective and reversible inhibition of monoamine oxidase (MAO) B, without an MAO-A effect.
- Selective sodium (Na+) channel blockade, affecting neurons with abnormal firing patterns, but not those with normal activity.
- Calcium (Ca2+) channel modulation.
Deal Structure: Safinamide was previously developed by Pharmacia & Upjohn (P&U). Newron acquired the rights to safinamide from P&U at the end of 1998.
Newron and Merck KGaA
In October 2006, Newron Pharmaceuticals granted Serono exclusive worldwide rights to develop, manufacture and commercialise safinamide in Parkinson's disease (PD), Alzheimer's disease, and other cognitive disorders. Under the terms of the agreement, Serono will be responsible for all future development, manufacture and commercialisation costs. Serono will make an upfront payment and additional milestone payments to Newron of up to $200 million based on defined development and commercialization achievements in all major markets. Serono will also pay Newron undisclosed royalties on worldwide net sales. In addition, Newron will have the right to opt for co-promotion with Serono in Italy and Spain.
In January 2007, the acquisition of Serono S.A. (now Merck Serono S.A.) by Merck KGaA and the integration of the business...See full deal structure in Biomedtracker
Partners: Meiji Seika Pharma Co., Ltd Zambon Company S.p.A. US WorldMeds, LLC
Additional information available to subscribers only: